Treatment eligibility

Treatment eligibility criteria

Treatment candidate

Contraindicated patient

Treatment eligibility

MRI-based contraindications

- A history of macrohemorrhages
- More than 4 microhemorrhages
- Evidence of superficial siderosis
- Evidence of brain vasogenic edema
- Significant white matter hyperintensities
- Multiple lacunar strokes
- Cerebral strokes involving a major vascular territory
- Central nervous system infection
- Evidence of cerebral contusion, encephalomalacia, brain aneurysms or other vascular malformations
- Brain tumors other than meningioma
- Arachnoid cysts
- Evidence of underlying cerebral amyloid angiopathy-related inflammation
- Evidence of Amyloid-Beta-related angiitis

Treatment eligibility



Explainable artificial intelligence



Presence of macrohemorrhages

Number of microhemorrhages

Presence of superficial siderosis

Presence of vasogenic edema

White matter hyperintensity load

Number of lacunar infarcts

Treatment eligibility

The future of Alzheimer's treatment



Cummings, J. L., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., Leisgang-Osse, A. M., & Cheng, F. (2025). Alzheimer's disease drug development pipeline: 2025. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 11(2), e70098.

The future of Alzheimer's treatment



Thank you for your attention!

esten@baba-vision.com



baba vision